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Abstract
Background: Increased coronary intima media thickness (CIMT) has been associated with adverse cardiovascular
outcomes, as have increased glucose levels. The link has not been established between glucose and CIMT;
therefore, we sought to assess the relationship between glucose and CIMT.
Methods: Medline, EMBASE, Scopus, and Cochrane databases were searched from inception through 2009 for
original research reporting both postprandial glucose levels and CIMT measurements. Glucose was classified as
normal, impaired, or diabetic. Outputs included inverse variance weighted effect size and also average correlation
(using the Wang and Bushman approach). Data were combined using a random effects meta-analytic model.
Heterogeneity as assessed using c
2 and I
2; bias was examined using Egger plots and Begg-Mazumdar tau.
Polynomial functions (i.e., linear, quadratic, cubic, quartic) were fit to the data and the Akaike Information Criteria
were used to select the optimal model.
Results: We identified 172 papers; 161 were rejected (19 inappropriate design, 8 had selected patients, 101
inappropriate outcomes) leaving 11 accepted. We used data from 15,592 patients (8250 normals, 3013 impaired
glucose, 4329 diabetics). There was no evidence of heterogeneity or publication bias. The overall correlation was
0.082 (CI95%:0.066-0.098); the overall effect size was 0.294 (0.245-0.343) between diabetics and normals and 0.137
(0.072-0.202) between normals and those with impaired glucose. The equation of best fit was linear (CIMT = 0.828
+ 0.009*glucose).
Conclusions: There is a small but significant relationship between postprandial glucose levels and CIMT, which
have both been associated with adverse cardiovascular outcomes.
Background
The National Institutes of Health defines atherosclerosis
as “an arteriosclerosis characterized by atheromatous
(i.e., fatty) deposits in and fibrosis of the inner layer of
the arteries” [1]. The major locus for the formation of
atherosclerotic plaques is in the carotid arteries. The
p r o b l e ms t a r t sa tt h ep o i n tw h e r et h ec o m m o nc a r o t i d
artery bifurcates into the internal and external branches.
Progression occurs mainly along the proximal part of
the common carotid artery and into the proximal
section of the internal carotid artery.
In middle aged men, the intima and media of the
common carotid artery together measure from 0.7-1.2
mm [2]. The American Heart Association also noted
that the arterial intima is not of uniform thickness, with
normal arteries having an intima: media ratio of 0.1 to
1.0, or even more. Increases in carotid intima media
thickness (CIMT) are associated with a number of fac-
t o r s ,i n c l u d i n ga g e ,s e x ,h y p e r t e n s i o n ,s m o k i n g ,l i p i d
profile, and body mass index [3]. Lorenz et al. [4] have
referred to CIMT as “an intermediate phenotype for
early atherosclerosis”. This marker for disease has an
advantage in that it can be measured rather easily with
ultrasonography, which is alson o n - i n v a s i v e[ 5 ] .T h e r e -
fore, it may be used to screen large groups of patients.
Ceriello [6] has linked hyperglycemia to cardiovascular
disease through a series of relationships. He proposed
that hyperglycemia creates oxidative and nitrosative
stress, which act on the arterial wall to initiate the thick-
ening process. Brohall and associates [7] reported that
impaired glucose tolerance was not associated with
atherosclerosis, but it was associated with intima medial
thickness. Epidemiologic support for an overall
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coworkers [8] who performed a meta-analysis of studies
to date. They found a positive relationship between
postprandial glucose levels in non-diabetics and the
later development of cardiovascular events (CVEs),
including myocardial infarction, stroke, and death. In
2007, Lorenz and coworkers [4] published a meta-analy-
sis that investigated the relationship between CIMT and
those same CVEs. They concluded that CIMT strongly
predicted future vascular events, with a relative risk per
CIMT difference that was somewhat greater for stroke
than for myocardial infarction.
A search of the literature could find no studies that
have definitively quantified the link between glucose
levels and CIMT. If the theory proposed by Ceriello is
correct, then there should be supporting evidence from
epidemiologic studies. Therefore, the purpose of the
present research was to quantify the relationship
between blood glucose levels and CIMT. There were
two specific aspects of interest, which were inference
and modeling. The inferential analysis focused on esti-
mating the correlation between CIMT and glucose and
to test whether this relationship was statistically signifi-
cant. The modeling analysis focused on fitting a series
of regression models to the dataset and choosing the
optimal model to represent the data.
Methods
We sought to retrieve all research studies of persons
who had both CIMT measurements and blood glucose
levels. Patients could have any glucose status, but the
studied sample could not consist exclusively of diabetics;
there must have been at least one group of non-dia-
betics. Papers could be published in any language at any
time. The following databases were searched from the
date they started until the end of 2009: Medline,
EMBASE, Scopus, and Cochrane. Search terms included
“glucose” or “blood sugar” and “CIMT” or “coronary
artery media” or “stenosis” or “medial thickness”,a n d
combinations thereof. Two reviewers performed the
search and a third adjudicated discrepancies and inde-
pendently verified all steps of the process.
Data extracted included the means and standard
deviations for CIMT and 2-hour post prandial glucose
levels. For data analysis, we classified glucose levels by
groups corresponding to the categories of diabetes as
defined by the American Diabetes Association [9],
which were normal, impaired, and diabetic. If glucose
levels by group were unavailable, the boundary values
(7.8, 9.45, and 11.1 mmol/L) were imputed. If the article
reported more than three subgroups related to glucose
levels, the weighted averages of the estimates (using
means and standard deviations) from the relevant sub-
groups were computed.
Using these means and standard deviations, and
assuming a normal distribution, five hundred datasets
per study were simulated and the average correlation
coefficient and related confidence interval were com-
puted per study [10]. Applying the method from Wang
and Bushman [11], the overall estimate for the correla-
tion (i.e., Pearson’s r) and its confidence interval were
computed. The macros ‘wavgmeta’ and ‘covtefst’ were
used to compute the weighted average correlation esti-
mates [11,12]. A forest plot was used to depict and sum-
marize the individual and overall correlations.
In order to model the overall relationship between
CIMT and glucose over the range of reported glucose
levels, a series of polynomial functions (i.e. linear, quad-
ratic, cubic, quartic) were fit to the data [13,14]. The
Akaike Information Criterion (AIC) were used to select
the optimal model. It is calculated as AIC = 2k - 2 ln
(L), with k being the number of parameters and L being
the maximized value of the likelihood function for the
estimated model. This index is used to select between
competing models. The original application was for
time-series models, but it may also be applied to regres-
sion models. The AIC considers both the goodness of fit
and number of parameters in the model, with lower
values of the index (which are associated with the fewest
parameters) being preferred.
In addition to the correlation analysis, effect sizes were
calculated to quantify the relationship between the dia-
betic group and the normal group as well as between
the impaired group and the normal group. Forest plots
were used to summarize the computed effect sizes and
related confidence intervals.T ot e s tf o rh e t e r o g e n e i t y
between studies, the Cochran Q test [15] and the I
2
tests [16,17] were performed. In order to test for bias,
the Egger [18] and Begg-Mazumdar [19] tests were per-
formed. The software packages used in this analysis
were SAS (SAS Institute Inc., Cary, NC) and StatsDirect
(StatsDirect Ltd., Cheshire, UK).
Results
The initial screening identified 172 potential papers, of
which 161 were rejected (19 had inappropriate study
designs, 8 dealt with specific selected disease states, and
134 had inappropriate outcomes (101 did not report
glucose levels in ≥3q u a n t i l e s ,2 4d i dn o ti n d i c a t et h e
numbers of outcomes within each quantile, and 9 did
not report CIMT values). That left 11 acceptable studies
for the analysis, which are summarized in Table 1
[20-30].
Correlation coefficients are presented in Table 1.
Their values ranged from -0.02 to 0.180, with an average
of 0.082 (CI95%: 0.061-0.094), which is small but indi-
cates a significant relationship that is beyond chance.
The tests for heterogeneity were non-significant
Einarson et al. Cardiovascular Diabetology 2010, 9:37
http://www.cardiab.com/content/9/1/37
Page 2 of 8(Cochran’s Q = 10.44, P = 0.40; I
2 =4 . 2 % ) .E g g e r ’st e s t
found no evidence of bias (intercept = 0.55, P = 0.59),
as did the Begg-Mazumdar statistic (τ = 0.052; P =
0.52). Therefore, results were considered combinable.
The results of the correlation analysis (per study and
overall) are listed in Table 1 and depicted in Figure 1.
The correlations coefficients from 8 (73%) of the 11
articles were positive and statistically significant, as was
the overall correlation (r = 0.082; 95% confidence limits
0.066, 0.098). Cohen [31] would define that value as
small, but positive.
A series of polynomial regression models were then
fit to the glucose and carotid intima media thickness
estimates. Using the AIC criteria, the linear model
Table 1 Characteristics of the accepted studies and correlation of post prandial glucose level with CIMT.
Number of persons studied Correlation coefficient
Glucose category Glucose Pearson’sr
Author Year normal impaired diabetic Total Groups* (95% CI)
Faeh[1] 2007 776 150 184 1,110 3 0.075 (0.017-0.133)
Henry[2] 2004 278 168 301 747 3 0.094 (0.022-0.164)
Hunt[3] 2003 1,127 66 303 1,496 3 0.124 (0.074-0.174)
Ishizaka[4] 2003 738 334 166 1,238 3 0.056 (0-0.164)
Mohan[5] 2006 1,600 330 1,500 3,430 4 0.086 (0.053-0.119)
O’Leary[6] 1992 2,576 1,427 1,161 5,164 3 0.069 (0.042-0.096)
Niskanen[7] 1996 98 21 84 203 3 0.104 (-0.034-0.238)
Rajala[8] 2002 57 97 54 208 3 0.085 (-0.051-0.218)
Temelkova[9] 2000 265 82 88 435 4 0.180 (0.088-0.270)
Tuomilehto[10] 1998 100 25 44 169 3 -0.020 (-0.169-0.131)
Wagenknecht[11] 1998 635 313 444 1,392 4 0.077 (0.024-0.129)
Overall 8,250 3,013 4,329 15,592 0.082 (0.066-0.098)
*Indicates the number of glucose categories reported. In the Temelkova study, four groups were reported; however, only three were used for the analysis
Figure 1 Forest plot of correlations between CIMT and postprandial glucose.
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Page 3 of 8(Y = a + b*X; Y = CIMT, X = Glucose, a =0 . 8 2 8 ,b =
0.009) was chosen as having the best fit, since it had the
lowest value of -6.5. The relationship between carotid
intima media thickness is plotted in Figure 2 with the
regression function overlaid.
The calculated effect sizes from the accepted studies
are presented in Table 2; forest plots appear in Figures
3 and 4. All tests for heterogeneity were non-significant
(I
2 = 24% and Cochran’s Q = 13.07, P = 0.22 for nor-
mals; I
2 = 37% and Q = 15.85, P = 0.10 for impaired
glucose. Egger’s test found no evidence of publication
bias (intercepts = -0.08, P = 0.91 and 0.60, P = 0.44,
respectively), nor did the Begg-Mazumdar test (τ =
-0.05, P = 0.76 and τ = 0.13, P = 0.65, respectively). The
overall effect size between diabetics and normals was
0.294 (CI95%: 0.245-0.343), which Cohen [31] would
define as small. The effect size between those with
impaired glucose and normals was 0.137 (CI95%: 0.072-
0.202), which is also small, but also significant.
Discussion
In a very thorough review of the evidence based litera-
ture, Helfand et al. 2009 [32] found that there were as
yet no accepted categories that could be effectively used
for cardiac risk assessment. They also noted that
epidemiologic studies used a variety of measurements,
but that there was no established consensus for which
was the best for assessing cardiovascular risk.
Unlike other studies that have examined glucose and
its relationship to subsequent cardiovascular outcomes,
Figure 2 Equation of best fit for the relationship between CIMT and glucose.
Table 2 Effect sizes (95% confidence limits) for the
difference in CIMT between categories of post prandial
glucose levels.
Glucose categories being compared
Diabetic-Normal Impaired-Normal
Faeh[1] 0.331 (0.170, 0.493) 0.187 (0.012, 0.362)
Henry[2] 0.293 (0.129, 0.457) 0.300 (0.107, 0.492)
Hunt[3] 0.401 (0.273-0.528) 0.326 (0.078-0.575)
Ishizaka[4] 0.239 (0.071, 0.408) 0.122 (-0.006, 0.252)
Mohan[5] 0.304 (0.233, 0.375) 0 (-0.118, 0.118)
O’Leary[6] 0.279 (0.210, 0.349) 0.125 (0.060, 0.189)
Niskanen[7] 0.379 (0.085, 0.673) 0.081 (-0.390, 0.552)
Rajala[8] 0.288 (-0.085, 0.662) 0.072 (-0.254, 0.399)
Temelkova[9] 0.477 (0.233, 0.721) 0.374 (0.125, 0.623)
Tuomilehto[10] -0.082 (-0.437, 0.271) -0.030 (-0.469, 0.407)
Wagenknecht[11] 0.192 (0.070, 0.313) 0.058 (-0.076, 0.194)
Overall 0.294 (0.245, 0.343) 0.137 (0.072, 0.202)
Einarson et al. Cardiovascular Diabetology 2010, 9:37
http://www.cardiab.com/content/9/1/37
Page 4 of 8the data pool in our study was much more restricted
due to the nature of the screening process. That is,
CIMT imaging is only done when there is a reason to
do so; seldom were there random screenings of the gen-
eral population. Most likely reasons include the expense
involved and time commitment. As well, the measure-
ment of CIMT does not have a long history. It has only
been done since Poli and coworkers initially described
the technique in 1988 [5].
This analysis indicates there is significant relationship
between intima medial thickness and glucose levels. The
overall correlation (r = 0.082) was positive and the con-
fidence interval did not include zero. Similarly, of the
individual studies, 8 of the 11 (73%) were positive and
statistically significant (i.e., the confidence intervals do
not include zero). The absolute value of the correlation
a n de f f e c t ss i z e si sn o tl a r g e ,b u tt h a ti st ob ee x p e c t e d
f r o mt h et y p eo fd a t at h a tw ew e r ea b l et ou t i l i z ei nt h e
analysis. The glucose values were reported in categories;
if actual means had been available, the estimates would
have been more precise.
The regression analysis identified a modest positive
relationship between CIMT and post-prandial glucose
levels. The regression line plot indicates the positive
linear relationship between these two factors, and the
linear regression function is preferred to the higher
order functions. Again, it has similar limitations due to
the measurement of the outcome data.
The conclusions of the effect size analysis are consis-
tent with the conclusions of the correlation analysis.
There was a positive and statistically significant relation-
ship between CIMT and post-prandial glucose levels.
Tests for heterogeneity and bias did not indicate the
presence of these factors.
These findings confirm those of Ceriello [6] and estab-
lish that there is a statistically significant link between
post prandial glucose levels and CIMT. Previous reviews
have established that increased CIMT does lead to
adverse cardiovascular outcomes. In 2002, Cheng’s
group published a review of all of the available studies
finding a positive relationship in more than 2000
patients [33]. Furthermore, when the CIMT was
reduced, cardiovascular events decreased. A larger
review by Brohall and colleagues [34] in 2006 examined
24,111 patients in 23 studies of type-2 diabetics and per-
sons with abnormal glucose tolerance. They found a
40% increase in strokes among diabetics and a smaller
increase in glucose intolerant persons. The strongest
Figure 3 Forest plot of effect sizes between CIMT and post prandial glucose levels in diabetics versus normals.
Einarson et al. Cardiovascular Diabetology 2010, 9:37
http://www.cardiab.com/content/9/1/37
Page 5 of 8quantitative evidence was provided in 2007 by Lorenz
and coworkers [4], who published a meta-analysis of
data from 37,197 patients in 8 studies that were
described in 12 papers. For every 0.1 mm increase in
CIMT, there was a 10% increase in the risk of myocardial
infarction and a 13-18% increase in the risk for stroke.
More recently, a clinical study in type-2 diabetics by
Djaberi et al. [35] reported a significant relationship
between CIMT and abnormal cardiac perfusion. These
results could help explain the sequence of events. Other
recent publications provide additional information,
including papers by Ito and coworkers [36], Escobedo
and colleagues [37], and Poppe and associates [38].
These articles confirm that vascular imaging can be
effectively used to detect subclinical disease in type 2
diabetics and potentially predict cardiovascular risk.
Escobedo’s group [37] found that abnormalities in
CIMT were widespread in Latin America, suggesting
that screening might be an option. Ito’s study [36] estab-
lished the relationship between increased CIMT and
glomerular filtration rate, a marker for kidney disease, as
well as diabetic nephropathy. Finally, the Poppe group
[37] determined that CIMT and carotid plaque
increased in concert with the number of factors asso-
ciated with metabolic syndrome. Such findings are in
agreement with what we have reported in the present
research.
Among the limitations of this study is the small num-
ber of studies available for analysis. Ideally, larger num-
bers are preferable, but these are what could be found
in the literature. Nonetheless, we did analyze data from
more than 15,000 patients, which does afford some
degree of confidence in the findings. As well, we exam-
ined only post prandial glucose levels. It may well be
that fasting levels would produce more robust results.
Another option would be to examine the relationship
between glycosylated haemoglobin and CIMT. In addi-
tion, we were not able to adjust for potential confoun-
ders, as they were not uniformly reported across all
studies, rendering meta-regression non-feasible.
Conclusions
We have demonstrated that a significant relationship
exists between post prandial glucose levels and CIMT.
These events, in turn, have been associated with adverse
cardiovascular events such as stroke and myocardial
Figure 4 Forest plot of effect sizes between CIMT and post prandial glucose levels in persons with impaired glucose tolerance versus
normals.
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Page 6 of 8infarction. Since the measurement of CIMT is non-
invasive, it may prove to be a useful tool both in
diagnosing potential problems, but also in monitoring
treatments and their outcomes.
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